Published Studies Related to Piperacillin and Tazobactam (Piperacillin / Tazobactam)
Well-designed clinical trials related to Piperacillin and Tazobactam (Piperacillin / Tazobactam)
Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. [2011.05]
Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). [2011.02]
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. [2010.08]
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. [2010.08]
Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. [2010.04]
Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. [2010.04]
Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. [2009.10]
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. [2009.07]
Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. [2009.04]
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? [2009.03]
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. [2008.12]
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. [2008.07]
Pharmacoeconomics of Ciprofloxacin plus Metronidazole vs. Piperacillin-Tazobactam for Complicated Intra-Abdominal Infections. [2008.06]
Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. [2008.06]
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. [2008.05]
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. [2007.08]
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. [2007.02]
Well-designed clinical trials possibly related to Piperacillin and Tazobactam (Piperacillin / Tazobactam)
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
A protocol for a multicentre randomised controlled trial of continuous
beta-lactam infusion compared with intermittent beta-lactam dosing in critically
ill patients with severe sepsis: the BLING II study. [2013]
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter
double-blind, randomized controlled trial. [2013]
[Perioperative antibiotic prophylaxis in radical retropubic prostatectomy: a randomised pilot study of perioperative and postoperative administration]. [2011.01]
Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. [2009.10]
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. [2007.08]
Comparative effects of single-dose ceftriaxone versus three oral antibiotic regimens on stool colonization by resistant bacilli in children. [2007.01]
Other research related to Piperacillin and Tazobactam (Piperacillin / Tazobactam)
Prospective randomized comparison study of piperacillin/tazobactam and meropenem
for healthcare-associated pneumonia in Japan. [2013]
Randomized comparison of piperacillin-tazobactam plus amikacin versus
cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in
children with lymphoma and solid tumors. [2013]
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed
by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections:
results of the RELIEF study. [2013]
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam
in healthy adult subjects. [2012]
Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. [2011.12.15]
Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis. [2011.12]
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. [2011.11]
The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. [2011.08]
Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia. [2011.06.14]
Drug fever due to piperacillin/tazobactam loaded into bone cement. [2011.02]
Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. [2011.02]
Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient. [2011]
Microbiological equivalence of bacteriostatic and bactericidal activities of the
sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz)
and original piperacillin/tazobactam (Tazocin). [2011]
Piperacillin/tazobactam versus cefozopran for the empirical treatment of
pediatric cancer patients with febrile neutropenia. [2011]
[Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward]. [2010.12]
Delayed-type hypersensitivity reaction to piperacillin/tazobactam in a patient with an infected total knee replacement. [2010.11]
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. [2010.10]
Pharmacokinetic evaluation of piperacillin-tazobactam. [2010.08]
Electrolytes imbalance: a rare side effect of piperacillin/ tazobactam therapy. [2010.06]
The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections. [2010.06]
Daily serum piperacillin monitoring is advisable in critically ill patients. [2010.05]
Protective Effect of Citropin 1.1 and Tazobactam-Piperacillin Against Oxidative Damage and Lethality in Mice Models of Gram-Negative Sepsis. [2010.04.20]
Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital. [2010.04.15]
Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis. [2010.04]
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. [2010.03.18]
Piperacillin-associated pulmonary infiltrates with eosinophilia: a case report. [2010.03]
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. [2010.02]
Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports. [2010]
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk
for aspiration: comparison with imipenem/cilastatin. [2010]
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as
empirical treatment of febrile neutropenia in cancer patients: results of an open
randomized trial at a university hospital. [2010]
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot
infections: a prospective, randomized clinical trial in a university hospital. [2010]
Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile
neutropenia. [2010]
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials. [2009.12.02]
Haemolytic anaemia caused by piperacillin-tazobactam. [2009.11]
Other possibly related research studies
[Susceptibility of Escherichia coli strains isolated from persons with urinary tract infections in 2007 - 2008 to antimicrobial agents] [2010]
Late onset postpneumonectomy empyema presenting 24 years after pneumonectomy. [2010.07]
Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against gram-negative bacteria collected from Shenyang, China. [2010.06.15]
Ventilator-associated pneumonia due to Shewanella putrefaciens. [2010.06.15]
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. [2010]
Clinical presentations, prognostic factors, and mortality in patients with Aeromonas sobria complex bacteremia in a teaching hospital: a 5-year experience. [2009.12]
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. [2010.03]
Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains. [2010.07]
Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit. [2010.05]
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. [2010.04.01]
Antibiotic prescription patterns in hospitalized patients with nursing home-acquired pneumonia. [2010.03]
Clinical predictors and risk factors for relapsing Clostridium difficile infection. [2010.04]
Septic shock in digestive surgery: a retrospective study of 89 patients. [2009.11]
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. [2010.05]
Treatment of Acinetobacter infections. [2010.04]
False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. [2010.07]
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. [2010.05]
Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. [2010]
Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. [2010.02]
Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration. [2010.01.29]
Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. [2009.11]
In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals. [2009.11]
Complicated intra-abdominal infections: a focus on appendicitis and diverticulitis. [2010.01]
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. [2010.03]
[Multidrug-resistant Acinetobacter baumannii infection in respiratory intensive care unit] [2009.10]
[Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis] [2009.10]
Epidemiology and susceptibility to antimicrobials in community, hospital and long-term care facility bacteremia in northern Israel: a 6 year surveillance. [2009.10]
Fibrin ring granulomas in Rickettsia typhi infection. [2010.03]
Francis Tally and the discovery and development of tigecycline: a personal reminiscence. [2010.01.01]
Three decades of beta-lactamase inhibitors. [2010.01]
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. [2010.03]
Optimizing empirical antimicrobial therapy for infection due to gram-negative pathogens in the intensive care unit: utility of a combination antibiogram. [2010.03]
In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. [2009.12]
Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. [2010.04]
Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes. [2010.02]
The treatment of diabetic foot infections: focus on ertapenem. [2009]
Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline Evaluation and Surveillance Trial, 2004-2009. [2011.11.19]
[Severe acute respiratory distress syndrome complicating type A (H1N1) influenza treated with extracorporeal CO2 removal]. [2011.04]
[Changes in the incidence of multiresistant pathogens and its consequences in the intensive care unit]. [2011.09.11]
Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia. [2011.09]
Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009. [2011.04.15]
[Infections related to central venous catheters in children affected from malignant diseases]. [2011.06.27]
Ciprofloxacin use and susceptibility of Gram-negative organisms to quinolone and non-quinolone antibiotics. [2011.09]
|
